ELV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Elevance Health is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to act now. The stock has a solid long-term quality profile and analyst sentiment is improving, but current fundamentals are mixed and the technical setup is extended enough that this is not an attractive immediate entry. My direct view: hold and wait for a better pullback rather than buying today.
ELV is in an uptrend on the chart, with bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram at 2.331, though it is contracting, which suggests momentum is still positive but fading. RSI_6 is 72.64, indicating the stock is near overbought territory rather than offering a clear bargain. Price at 372.95 is just below resistance at 376.221 and above pivot support at 362.805, so the stock is extended near a resistance zone instead of sitting at an ideal entry.
["BofA upgraded ELV to Buy and raised the price target to $435, showing improving Street confidence.", "JPMorgan, Barclays, Guggenheim, Jefferies, and Truist all maintained positive or constructive views with price-target increases.", "Health insurer sentiment is improving broadly after peers like UnitedHealth and Cigna beat Q1 expectations despite higher medical costs.", "Analysts believe medical reserves are strengthening, which could support earnings in 2026 and later margins.", "Insider buying has increased 132.13% over the last month, which is a positive signal."]
["Q1 financials were mixed: revenue rose 2.64% YoY, but net income fell 19.19% and EPS fell 16.75% YoY.", "Hedge funds are selling, with selling up 135.25% over the last quarter.", "Congress trading shows 1 sale and 0 purchases in the last 90 days, which is a bearish sentiment signal.", "Near-term analyst commentary still points to risks around Medicaid margins, exchanges, and acuity.", "The stock is trading close to resistance and recent trend models suggest limited upside in the next month."]
Latest quarter: Q1 2026. Revenue increased to $50.181 billion, up 2.64% year over year, which shows modest top-line growth. However, net income dropped to $1.764 billion, down 19.19% YoY, and EPS fell to $8.00, down 16.75% YoY. That means growth was present, but profitability weakened in the latest quarter.
Analyst sentiment has turned more positive recently. BofA upgraded ELV to Buy and lifted its target to $435, while JPMorgan raised its target to $411 and kept Overweight. Barclays, Guggenheim, Jefferies, and Truist also remain constructive with target increases or Buy/Overweight ratings. The bearish side is that some firms remain neutral, such as Leerink and Baird, but the overall Street view is leaning bullish. Pros: stronger margin outlook, improving reserve trends, and multiple target hikes. Cons: near-term Medicaid and utilization risks, and some analysts still see only gradual recovery.
